R&D
Research & Development
Kolon Pharmaceuticals is dedicated to innovating and creating value through relentless research and development.
Pileline Stautus
| Category | 2021 | 2022 | 2023 | 2024 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | ||
| Drug Development | PBS203 | Hit to Lead Optimization | CMC/Non-Clinical or Preclinical | Clinical | PV Establish / 1,2PD Study & MoA Study | ||||||||||||
| Joint Development | PBL201 | PV Establish / Activity Test | CMC/Non-Clinical or Preclinical | Clinical | PV Establish / 1,2PD Study & MoA Study | ||||||||||||
| PBL211 | PV Establish / Activity Test | CMC/Non-Clinical or Preclinical | Clinical | PV Establish / 1,2PD Study & MoA Study | |||||||||||||
Allostatine?
Hybrid Molecule Human Ig CDR3 and Alloferon
Interaction with NKG2D receptor
Alloferon
Human Ig CDR3
Allostatine & Alloferon - 13 Amino Acids
Alloferon : HGVSGHGQHGVHG
Allostatine : HGVSGWGQTHG
Human Ig CDR3 : SGWGQ-GT
NKG2D Allostatine Interaction
Blue Color : Negative Charge
Red Color : Positive Charge
Gold Color : Allostatine
Source : Prof. C. Rosano, Institute of Cancer Research, Italy
Anti-Cancer Effect of Combination Therapy
Validation of Combination Therapy in Orthotopic Pancreatic Cancer Model
Validation of Chemotherapy & Allostatine Combination in Anti-cancer Effect of Targeted Therapy
Orthotopic Pancreatic Cancer Model
Anti-Cancer Effect of Targeted Therapy
Validation of Chemotherapy & Allostatine Combination in Liver Metastasis Colon Cancer
Validation of Chemotherapy & Allostatine Combination in Orthotopic Cancer
Colon Cancer Liver Metastasis Model
Ovarian cancer Orthotopic Animal Model
Patent Application
Patent Application US Patent Application Priority of pancreatic cancer combination therapy
Extension of indication in ovarian cancer, colon cancer and any solid Tumor
Cancer Metabolism Target
Significant factors of tumor microenvironment
PRIINT Understanding & Targeting pancreatic cancer cell metabolism
Metabolism of immune cells in cancer
Target expression
Target expression of orthotopic model of pancreatic cancer
Colon cancer, Prostate cancer, Head & Neck cancer, Lymphoma
Analyzing orthotopic tissue biopsy
Nomal
Cell line 1Orthotopic transplant model tissue
Cell line 2Orthotopic transplant model tissue
Cell line 3Orthotopic transplant model tissue
Target expression of patient tissue
Colorectal cancer
Breast cancer
Prostate cancer
Lung cancer
Testis cancer
Target validation
Anti-cancer effect to novel target of pancreatic cancer
Validation of orthotopic pancreatic model with reference
Anti-cancer Effect of target of colon cancer
Anti-cancer Effect of Pancreatic Cancer Orthotopic Model
Hit to lead screening
In Vitro : Cell Line based pharmacology & Screening
Library screening
Virtual screening
Galectin-9(GB920)
One of the Glycoproteins : Multiple function in tumors
Activation of Apoptosis & Inhibition of Migration & Metastasis
On going study of K-RAS mutant type solid tumor & Mets cancer
Angiogenesis
Migration/invasion/metastasis
Apoptosis
Cell transformation
Thmor growth
Immune cell adhesion &
Immune escape
Natural form
Susceptible to proteases
(Thrombin , MMP3 , Elastase)
Mutant form : sGal-9 GB920
Resistant to proteases
Results of the study on the anti-cancer effect of Galectin-9
Galectin-9 : Interrupt tumor growth, Migration & Metastasis
Anti-cancer Effect in KRAS mutant type animal model
Interrupt Effect of metastasis in Melanoma, Colon cancer
Interrupt Effect of growth in Colon cancer mutant type
Anti-cancer Effect of sGal-9 in Pancreatic cancer mutant type
In this study, Interrupted growth & prolonged survival rate
GBIO test result
In In vitro anticancer effect
Cell growth interruption activation and cell death effects found in various solid cancer cell strings
Cellg rowth interruption
Apoptosis in DLD-1 Colon cancer
